Skip to main content
Download PDF

Retraction Note: Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies

BMC Neuroscience volume 26, Article number: 23 (2025) Cite this article

The Original Article was published on 26 November 2015

Retraction Note:

The Editor has retracted this article because of concerns regarding figures presented in this work. These concerns call into question the article's overall scientific soundness. An investigation conducted after its publication discovered the following issues:

  • A portion of the right half of Panel 3RTau mut tg, Vehicle | Dentate in Fig. 1a appears to overlap, when horizontally flipped, with a portion of the right half of Panel 3RTau mut tg, Cerebrolysin | Dentate in the same figure. These Panels represent tissues taken from animals which underwent different treatments;

  • A portion of the left half of Panel Non-tg, Vehicle | Dentate gyrus in Fig. 2a appears to overlap with a portion of the right half of Panel Non-tg, Cerebrolysin | Dentate gyrus in the same figure. These Panels represent tissues taken from animals which underwent different treatments;

  • A portion of Panel Non-tg, Vehicle | Neocortex in Fig. 2a appears to overlap when re-scaled, with Panel Non-tg, Cerebrolysin | Neocortex in Fig. 2c. These Panels represent tissues taken from animals which underwent different treatments;

  • A portion of Panel Non-tg, Cerebrolysin | Neocortex in Fig. 2a appears to overlap, when re-scaled, with a portion of the right half of Panel Non-tg, Vehicle | Neocortex in Fig. 2c. These Panels represent tissues taken from animals which underwent different treatments;

  • A portion of the left half of Panel Non-tg, Cerebrolysin | MPA2, 3–6 mo. in Fig. 4e appears to overlap, when re-scaled, with a portion of the left half of Panel 3RTau mut tg, Cerebrolysin | MPA2, 3–6 mo. in the same figure. These Panels represent tissues taken from animals subject to different experimental conditions.

The Editor therefore no longer has confidence in the integrity of the research presented in this article.

The authors have not replied to correspondence from the Publisher about this retraction. The Publisher has been informed that Edward Rockenstein has passed away.

Author information

Authors and Affiliations

  1. Department of Neurosciences, University of California, La Jolla, San Diego, CA, 92093‑0624, USA

    Edward Rockenstein, Kiren Ubhi, Michael Mante, Jazmin Florio, Anthony Adame & Eliezer Masliah

  2. Clinical Research and Pharmacology, EVER Neuro Pharma GmbH, Unterach, Austria

    Stefan Winter, Hemma Brandstaetter & Dieter Meier

  3. Department of Pathology, University of California, La Jolla, San Diego, CA, USA

    Eliezer Masliah

Authors
  1. Edward Rockenstein
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Kiren Ubhi
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Michael Mante
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Jazmin Florio
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Anthony Adame
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Stefan Winter
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Hemma Brandstaetter
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Dieter Meier
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Eliezer Masliah
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Eliezer Masliah.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12868-015-0218-7

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rockenstein, E., Ubhi, K., Mante, M. et al. Retraction Note: Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick’s disease and fronto-temporal tauopathies. BMC Neurosci 26, 23 (2025). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12868-025-00942-y

Download citation

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12868-025-00942-y

BMC Neuroscience

ISSN: 1471-2202

Contact us